Stemmer C, Briand J P, Muller S
Laboratoire d'Immunochimie, UPR 9021 CNRS, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France.
Mol Immunol. 1994 Oct;31(14):1037-46. doi: 10.1016/0161-5890(94)90099-x.
Seventeen synthetic peptides of 15-16 residues, covering the complete sequence of the major human H1b variant, were tested for their capacity to bind serum IgG antibodies from 128 patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's syndrome (pSS). One peptide (residues 111-127) of the human H1 degree variant and six synthetic and natural fragments of H5 were also tested. Results were compared to those obtained with antibodies from 11 rabbits immunized against chicken H1 and H5, and calf H1. The activity of peptides was tested in direct ELISA and in inhibition assays with free peptides in solution. A major epitope recognized by antibodies from SLE, RA and pSS patients as well as by rabbit antibodies was identified in the C-terminus of H1b (residues 204-218). Other peptides in the globular (residues 79-94) and C-terminal domains of H1b and peptide 111-127 of H1 degree were also recognized, albeit at a lower level and frequency, and some of them contain sequence homologies with peptide 204-218. Patients' antibodies and rabbit antisera were tested with complete H1 proteins from HeLa cells, calf thymus and chicken erythrocytes and with chicken H5. Less than 25% of autoimmune sera contained IgG antibodies reacting with H1/H5 in a direct ELISA. In dot-immunoassay, antigenic activity with intact H1/H5 proteins was detected in a larger number of sera. Using antibodies raised in rabbits against peptides 1-16 and 204-218 of H1b, we found no reaction with H1 immobilized on a solid-phase. In contrast, peptides 144-159, 170-185 and 204-218, which contain identical structural domains, compete with H1 in solution indicating that any of these three regions are accessible at the surface of free H1 and may be involved in the induction of specific antibodies in autoimmune patients.
对17条含15 - 16个残基的合成肽进行了测试,这些肽覆盖了主要人类H1b变体的完整序列,以检测它们与128例系统性红斑狼疮(SLE)、类风湿关节炎(RA)和干燥综合征(pSS)患者血清IgG抗体结合的能力。还测试了人类H1度变体的一条肽(残基111 - 127)以及H5的六个合成片段和天然片段。将结果与用11只免疫了鸡H1和H5以及小牛H1的兔子的抗体所获得的结果进行比较。在直接ELISA以及用溶液中的游离肽进行的抑制试验中测试了肽的活性。在H1b的C末端(残基204 - 218)鉴定出一个主要表位,该表位被SLE、RA和pSS患者的抗体以及兔子抗体所识别。H1b球状结构域(残基79 - 94)和C末端结构域中的其他肽以及H1度的肽111 - 127也被识别,尽管水平和频率较低,并且其中一些与肽204 - 218具有序列同源性。用来自HeLa细胞、小牛胸腺和鸡红细胞的完整H1蛋白以及鸡H5对患者的抗体和兔子抗血清进行了测试。在直接ELISA中,不到25%的自身免疫血清含有与H1/H5反应的IgG抗体。在斑点免疫测定中,在更多血清中检测到了与完整H1/H5蛋白的抗原活性。使用针对H1b的肽1 - 16和204 - 218在兔子中产生的抗体,我们发现与固定在固相上的H1没有反应。相反,包含相同结构域的肽144 - 159、170 - 185和204 - 218在溶液中与H1竞争,表明这三个区域中的任何一个在游离H1表面都是可及的,并且可能参与自身免疫患者中特异性抗体的诱导。